Skip to main content

SeqWright to Use 454, NimbleGen Tools in Eli Lilly Collaboration

NEW YORK (GenomeWeb News) – Genomic services company SeqWright will use technologies from Roche subsidiaries 454 Life Sciences and NimbleGen to help drug developer Eli Lilly to identify genetic variants associated with psychiatric diseases, Roche said today.

Under the collaboration, SeqWright will use NimbleGen Sequence Capture technology to enrich around 40 megabases of the human genome, which will then be sequenced using 454 Life Sciences Genome Sequencer FLX System.

Eli Lilly's Brian Edmonds, a research advisor for global external research and development, in a statement called the genomic studies "a way to better examine the root causes of various psychiatric diseases. If this project delivers as expected, we hope to identify new biomarkers or novel drug targets for future development of medicines to treat an array of psychiatric illnesses."

Roche did not specify which psychiatric diseases the research would focus on.

Financial terms of the agreement were not released.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.